Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2019 | Astrocytoma | Original Article

Re-evaluation of the diagnostic performance of ¹¹C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas

Authors: Dongwoo Kim, Joong-Hyun Chun, Se Hoon Kim, Ju Hyung Moon, Seok-Gu Kang, Jong Hee Chang, Mijin Yun

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2019

Abstract

Purpose

We evaluated the usefulness of ¹¹C-methionine (MET) positron emission tomography/computed tomography (PET/CT) for grading cerebral gliomas according to the 2016 WHO classification with special emphasis on the presence of the isocitrate dehydrogenase 1 (IDH1) gene mutation and 1p/19q codeletion.

Methods

In total, 144 patients underwent MET PET/CT before surgery. The ratios of the maximum standardized uptake value (SUV) of the gliomas to the mean SUV of the contralateral cortex on MET PET/CT (MET TNR) were calculated.

Results

The median MET TNRs in IDH1-mutant and IDH1-wildtype tumours were 1.95 and 3.35, respectively. From among 74 IDH1-mutant tumours, the oligodendrogliomas showed a higher median MET TNR than the astrocytic tumours (2.90 vs. 1.40, P < 0.001). In grade II, III and IV IDH1-mutant astrocytic tumours, the median MET TNRs were 1.20, 2.05 and 2.20, respectively (grade II vs. grade III, P < 0.0001; grade II vs. grade IV, P = 0.023). In oligodendrogliomas, the MET TNR was lower fin grade II tumours than in grade III tumours (2.30 vs. 3.30 P = 0.008). In differentiating low-grade (grade II) from high-grade (grade III and IV) gliomas, receiver operating characteristic analysis showed a higher area under the curve for wildtype tumours (0.976) than for all tumours (0.852; P < 0.001) and IDH1-mutant tumours (0.817; P = 0.004).

Conclusion

IDH1-mutant tumours showed lower MET uptake than IDH1-wildtype tumours. Regardless of IDH1 mutation status, oligodendrogliomas with 1p/19q codeletion showed MET uptake as high as that in high-grade IDH1-wildtype tumours. Therefore, MET uptake for glioma grading was more consistent for IDH1-wildtype tumours than for IDH1-mutant tumours.

Available only for authorised users

Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40(4):615–35. https://doi.org/10.1007/s00259-012-2295-5.CrossRefPubMed

Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42(3):432–45.PubMed

Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol. 1984;119(1):29–34. https://doi.org/10.1002/jcp.1041190106.CrossRefPubMed

Narayanan TK, Said S, Mukherjee J, Christian B, Satter M, Dunigan K, et al. A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol. 2002;4(2):147–56.CrossRefPubMed

Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15(4):254–66. https://doi.org/10.1016/j.semcancer.2005.04.005.CrossRefPubMed

Ishiwata K, Kubota K, Murakami M, Kubota R, Senda M. A comparative study on protein incorporation of L-[methyl-3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol. 1993;20(8):895–9.CrossRefPubMed

Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50(5):1316–22.CrossRefPubMed

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMed

Akagi Y, Yoshimoto K, Hata N, Kuga D, Hatae R, Amemiya T, et al. Reclassification of 400 consecutive glioma cases based on the revised 2016 WHO classification. Brain Tumor Pathol. 2018;35(2):81–9. https://doi.org/10.1007/s10014-018-0313-4.CrossRefPubMed

10.

Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. 2018;45(3):443–51. https://doi.org/10.1007/s00259-017-3846-6.CrossRefPubMed

11.

Poetsch N, Woehrer A, Gesperger J, Furtner J, Haug AR, Wilhelm D, et al. Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naive gliomas. Neuro Oncol. 2018;20(3):411–9. https://doi.org/10.1093/neuonc/nox177.CrossRefPubMed

12.

Verger A, Taieb D, Guedj E. Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas? Eur J Nucl Med Mol Imaging. 2017;44(8):1408–10. https://doi.org/10.1007/s00259-017-3710-8.CrossRefPubMed

13.

Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44(7):1155–64. https://doi.org/10.1007/s00259-017-3618-3.CrossRefPubMed

14.

Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, et al. Prognostic value of O-(2-[18F]-fluoroethyl)-L-tyrosine-positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma. World Neurosurg. 2016;89:230–9. https://doi.org/10.1016/j.wneu.2016.01.085.CrossRefPubMed

15.

Kim D, Kim S, Kim SH, Chang JH, Yun M. Prediction of overall survival based on Isocitrate dehydrogenase 1 mutation and 18F-FDG uptake on PET/CT in patients with cerebral gliomas. Clin Nucl Med. 2018;43(5):311–6. https://doi.org/10.1097/RLU.0000000000002006.CrossRefPubMed

16.

Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, et al. IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur J Nucl Med Mol Imaging. 2017;44(8):1306–11. https://doi.org/10.1007/s00259-017-3668-6.CrossRefPubMed

17.

Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008;29(6):1176–82. https://doi.org/10.3174/ajnr.A1008.CrossRefPubMed

18.

Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayashi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015;42(6):896–904. https://doi.org/10.1007/s00259-015-2996-7.CrossRefPubMed

19.

Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53(11):1709–15. https://doi.org/10.2967/jnumed.111.102533.CrossRefPubMed

20.

Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99(2):217–25. https://doi.org/10.1007/s11060-010-0117-9.CrossRefPubMed

21.

Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238. https://doi.org/10.1038/srep16238.CrossRefPubMedPubMedCentral

22.

Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, et al. 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol. 2013;34(1):85–91. https://doi.org/10.3174/ajnr.A3173.CrossRefPubMed

Title: Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas
Authors: Dongwoo Kim
Joong-Hyun Chun
Se Hoon Kim
Ju Hyung Moon
Seok-Gu Kang
Jong Hee Chang
Mijin Yun
Publication date: 01-07-2019
Publisher: Springer Berlin Heidelberg
Keywords: Astrocytoma
Glioma
Glioma
Astrocytoma
Astrocytoma
Oligodendroglioma
Glioma
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04337-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Re-evaluation of the diagnostic performance of ¹¹C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2019

3′-Deoxy-3’-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies

Call to arms: need for radiobiology in molecular radionuclide therapy

Risk of ischaemic events at giant cell arteritis diagnosis according to PET/CT findings

Andrei Iagaru, Thomas Hope, Patrick Veit-Haibach (Eds): PET/MRI in Oncology. Current Clinical Applications

[18F]FDG PET/CT in non-union: improving the diagnostic performances by using both PET and CT criteria

Distinct FP-CIT PET patterns of Alzheimer’s disease with parkinsonism and dementia with Lewy bodies